Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

Implements significant cost reduction program Expects to be sustainably cash flow positive beginning 2H 2022 Investor conference call and webcast today at 8:00 AM ET (5:00 AM PT) DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 -- (Healthcar... Biopharmaceuticals, Personnel Theravance Biopharma, YUPELRI, revefenacin, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news